Tag : LDL-C

CONFERENCE UPDATE

Inclisiran-based strategy improves LDL-C goal attainment and safety: Results from the phase 4 VICTORION-Difference trial
STUDY DESIGN Atherosclerotic cardiovascular disease remains a substantial health burden, with low-density lipoprotein cholesterol established as a causal risk factor in both its development and progression.
CONFERENCE UPDATE

LDL-C reduction with lerodalcibep in patients at very high or high risk for CVD: The phase 3 LIBerate-HR study
Lerodalcibep is a third-generation proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor that prevents PCSK9 from binding to low-density lipoprotein receptors (LDLRs). Low-density lipoprotein-cholesterol (LDL-C) clearance from the bloodstream is enhanced as a result of LDLR degradation being blocked. Compared to monoclonal antibodies (mAbs), lerodalcibep is smaller in size and has a higher solubility, enabling prolonged and stable LDL-C reductions. In a prior phase 2 trial, lerodalcibep at a dose of 300mg monthly was shown to be effective in lowering LDL-C by >70%.
CONFERENCE UPDATE

“Inclisiran first” strategy lowers LDL-C in real-world ASCVD patients: Results from the VICTORION-INITIATE trial
A reduction in LDL-C is associated with improvements in CV outcomes in patients with ASCVD.1 As such, multiple guidelines recommend LDL-C targets of <55mg/dL and <70mg/dL based on baseline risks. However, many patients fail their LDL-C goals due to clinical inertia, medication nonadherence, side effects, and/or poor healthcare access. Inclisiran is a first-in-class siRNA that inhibits hepatic PCSK9 production and increases LDL receptor expression and LDL-C clearance. In clinical studies, twice-yearly administration of inclisiran has been shown to achieve a 50% reduction in LDL-C.